UBS Asset Management to join Future Cities Forum November event
Future Cities Forum is delighted that Zachary Gauge of UBS Asset Management will be joining our November infrastructure and development forum in the City of London. Zachary will join a panel discussion on healthcare and life sciences infrastructure.
This October UBS Asset Management’s Real Estate & Private Markets business announced the launch of its first UK life sciences property strategy, in partnership with Reef Group, with commitments of GBP 400 million from first close investors and a gross development value in excess of GBP 2.5 billion. Deploying a build-to-core approach, the Article 8 strategy seeks development opportunities in the life sciences sector, with a specific focus on good manufacturing practice (GMP) facilities.
Zachary was appointed Head of Research & Strategy Europe ex DACH of the Real Estate & Private Markets (REPM) business for UBS Asset Management (UBS-AM) in June 2021. He joined UBS-AM’s Real Estate Research & Strategy team in December 2014. His main role is to help the European real estate teams identify risks and opportunities traditional real estate sectors as well as the alternative markets, using a top-down macro-economic approach.
Zachary also delivers regular research-based views on the market to the internal fund management teams and external clients in both written and verbal form, and in addition, contributes to the bi-annual European commercial property forecasts, the development of fund strategies, new products and supports ongoing marketing and capital raising efforts. Zachary is a voting member of the European investment committee.
Prior to joining UBS Zachary worked at CBRE (2012–2014) on the EMEA research team with a focus on office occupational analysis and at Property Market Analysis (2010–2012) where he was responsible for analysing regional UK office and industrial markets.
Zachary holds the Investment Management Certificate (IMC).
As part of UBS AM's UK life sciences property strategy, four sites have been secured within the ‘Golden Triangle’ of London, Oxford and Cambridge, with a forecasted gross development value in excess of GBP 2.5 billion. This includes a joint venture with GSK in Stevenage to develop out a global innovation campus; a 500,000 square foot advanced manufacturing cluster in Stevenage’s town centre focusing on GMP; a pre-let GMP development opportunity in Greater London; and a lab-led opportunity in Oxford city centre.
UBS AM states:
'Central to the strategy is its social and environmental focus. The facilities will create significant local skilled employment opportunities, and in partnering with developer Reef Group, will provide fit-for-purpose, impactful buildings to companies focused on research and development (R&D) and healthcare innovations. Throughout the construction and operation of the facilities, UBS Asset Management will work with stakeholders to actively pursue net zero carbon emissions.'